EE6 COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
Nov 1, 2008, 00:00 AM
10.1016/S1098-3015(10)66190-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)66190-6/fulltext
Section Title :
Section Order :
24
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66190-6&doi=10.1016/S1098-3015(10)66190-6